Analysis of the FUSCC proteomic cohort revealed that ALDH18A1 was overexpressed in tumor (Fig. 7C), and once again, patients with elevated expression experienced a shorter OS (Fig. 7D). This evidence concerns the gene ALDH18A1 and neoplasm.